Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway

Kelly L Snider1, Michael L Maitland

  • 1Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA.

Targeted Oncology
|April 18, 2009
PubMed

Insights

Cardiovascular toxicities are a growing concern with angiogenesis inhibitors used in cancer treatment. Understanding their mechanisms can help optimize patient therapy and minimize side effects.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Angiogenesis inhibitors are increasingly used for cancer treatment.
  • Cardiovascular toxicities are recognized side effects of these drugs.
  • Understanding drug mechanisms is crucial for safe and effective use.

Purpose of the Study:

  • To review current concepts of cardiovascular toxicities associated with angiogenesis inhibitors.
  • To discuss the pharmacologic basis of these toxicities.
  • To explore optimizing the use of these agents for individual cancer patients.

Main Methods:

  • Literature review of angiogenesis inhibitors and their cardiovascular effects.
  • Analysis of pharmacologic mechanisms underlying drug-induced cardiotoxicity.
  • Discussion of therapeutic index factors and patient-specific optimization strategies.

Main Results:

  • Cardiovascular toxicities are a class effect of angiogenesis inhibitors.
  • Mechanisms of cardiotoxicity are being elucidated.
  • Pharmacologic understanding can guide personalized treatment approaches.

Conclusions:

  • Cardiovascular safety is a critical consideration in angiogenesis inhibitor therapy.
  • Further research into drug mechanisms will improve patient outcomes.
  • Optimizing treatment based on pharmacologic principles is essential for managing cancer patients.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...